They demonstrated that MAPK inhibitors significantly alter the HCC microenvironment and confirmed that BRAF and MEK inhibitors display dose-dependent antiproliferative and proapoptotic activities. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.